3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
10
INDUSTRY
2
OTHER_GOV
1
NIH
1
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Conditions
Breast Neoplasms
13
Glioblastoma
10
Glioma
7
Astrocytoma
6
Carcinoma, Non-Small-Cell Lung
5
Urinary Bladder Neoplasms
4
Neoplasms
4
Brain Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Stomach Neoplasms
2
Recurrence
2
Pancreatic Neoplasms
2
Oligodendroglioma
2
Melanoma
2
Carcinoma
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Diseases
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Seroma
1
Rectal Neoplasms
1
Pleural Neoplasms
1
Pleural Effusion, Malignant
1
Pleural Effusion
1
Pleural Diseases
1
Patient Preference
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Inflammatory Breast Neoplasms
1
Interventions
pembrolizumab
166
Nivolumab
111
Ipilimumab
93
Dacarbazine
44
trametinib
36
dabrafenib
34
Vemurafenib
33
binimetinib
23
atezolizumab
23
Temozolomide
21
cemiplimab
18
Paclitaxel
18
encorafenib
17
spartalizumab
16
cobimetinib
15
Carboplatin
14
talimogene laherparepvec
13
Cisplatin
13
Cyclophosphamide
12
lenvatinib
10
Pemetrexed
10
Gemcitabine
10
Docetaxel
10
durvalumab
9
Drug Therapy
9
Bevacizumab
9
tremelimumab
8
Injections
8
Albumin-Bound Paclitaxel
8
130-nm albumin-bound paclitaxel
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Melanoma
×
Surgical Procedures, Operative
×
Clear all
NCT03567889
2025-12-17
NeoDREAM
Philogen S.p.A.
Phase 3
Recruiting
186 enrolled
NCT02938299
2024-09-19
Pivotal
Philogen S.p.A.
Phase 3
Active not recruiting
214 enrolled